Copy to clipboard 
Zimmer Biomet reported 1Q26 orthopedic sales of $2 billion, up 9.3% compared to the first quarter of 2025. The company grew 2.9% on a constant currency, organic basis.
Creating a more dedicated and specialized sales force in the United States and some emerging markets is a major focus for Zimmer Biomet. An abundance of 1099 contractors has been an obstacle for the company as it tries to compete with direct reps.
“Nationwide, our average rep does around 7 cases per week,” said Zimmer Biomet CEO Ivan Tornos. “Our lead competitor is in the 16, 17 cases per week range. In the territories where we made the switches already, we’re seeing double-digit ranges for the number of cases. No surprise. When you go from spending 2 or 3 days a week doing cases to 5 days, you can imagine the productivity is going to increase.”
In terms of specialization, the company plans to add over 200 robotic clinical reps by the end of 2027 to support its diverse array of technologies. Zimmer Biomet completed enrollment in a 102 patient clinical study for its Mbos system acquired from Monogram, and expects to launch a semi-autonomous version in early 2027 followed by a fully autonomous version in late 2027/early 2028.
In knee replacement, Zimmer Biomet saw double-digit sales growth in its Oxford Partial Cementless Knee, but those gains were offset by pressure in legacy systems like NexGen and Vanguard that are being phased out. The company’s triple play in hip replacement – the Z1, OrthoGrid and HAMMR surgical impactor – is gaining nice traction in the market.
In the company’s S.E.T. category, shoulders remain strong while core trauma and orthobiologics continue to contend with headwinds. Foot and ankle returned to double-digit growth in the quarter.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $1,465.1 | $1,391.7 | $73.4 | 5.3% |
| Knees | $828.6 | $792.9 | $35.6 | 4.5% |
| Hips | $524.0 | $495.7 | $28.3 | 5.7% |
| Extremities | $112.5 | $103.1 | $9.5 | 9.2% |
| Trauma | $229.1 | $188.7 | $40.4 | 21.4% |
| Sports Medicine | $63.3 | $56.5 | $6.8 | 12% |
| Orthobiologics | $25.3 | $23.5 | $1.8 | 7.6% |
| Enabling Technology | $29.2 | $22.5 | $6.7 | 29.9% |
| Other | $274.7 | $226.3 | $48.5 | 21.4% |
| Total | $2,086.7 | $1,909.1 | $177.5 | 9.3% |
Orthopedic Sales by Geography
| Region | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,209.4 | $1,113.6 | $95.8 | 8.6% |
| OUS | $877.3 | $795.5 | $81.8 | 10.3% |
| EMEA | $516.5 | $458.2 | $58.3 | 12.7% |
| APAC | $266.1 | $253.0 | $13.1 | 5.2% |
| ROW | $94.8 | $84.4 | $10.4 | 12.3% |
| Total | $2,086.7 | $1,909.1 | $177.5 | 9.3% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $2,086.7 | |
| Cost of Sales | $576.2 | 27.6% |
| Selling and Admin | $849.9 | 40.7% |
| R & D | $103.4 | 5% |
| Other | $319.1 | 15.3% |
| Net Earnings | $238.1 | 11.4% |
Zimmer Biomet reported 1Q26 orthopedic sales of $2 billion, up 9.3% compared to the first quarter of 2025. The company grew 2.9% on a constant currency, organic basis.
Creating a more dedicated and specialized sales force in the United States and some emerging markets is a major focus for Zimmer Biomet. An abundance of 1099 contractors has...
Zimmer Biomet reported 1Q26 orthopedic sales of $2 billion, up 9.3% compared to the first quarter of 2025. The company grew 2.9% on a constant currency, organic basis.
Creating a more dedicated and specialized sales force in the United States and some emerging markets is a major focus for Zimmer Biomet. An abundance of 1099 contractors has been an obstacle for the company as it tries to compete with direct reps.
“Nationwide, our average rep does around 7 cases per week,” said Zimmer Biomet CEO Ivan Tornos. “Our lead competitor is in the 16, 17 cases per week range. In the territories where we made the switches already, we’re seeing double-digit ranges for the number of cases. No surprise. When you go from spending 2 or 3 days a week doing cases to 5 days, you can imagine the productivity is going to increase.”
In terms of specialization, the company plans to add over 200 robotic clinical reps by the end of 2027 to support its diverse array of technologies. Zimmer Biomet completed enrollment in a 102 patient clinical study for its Mbos system acquired from Monogram, and expects to launch a semi-autonomous version in early 2027 followed by a fully autonomous version in late 2027/early 2028.
In knee replacement, Zimmer Biomet saw double-digit sales growth in its Oxford Partial Cementless Knee, but those gains were offset by pressure in legacy systems like NexGen and Vanguard that are being phased out. The company’s triple play in hip replacement – the Z1, OrthoGrid and HAMMR surgical impactor – is gaining nice traction in the market.
In the company’s S.E.T. category, shoulders remain strong while core trauma and orthobiologics continue to contend with headwinds. Foot and ankle returned to double-digit growth in the quarter.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $1,465.1 | $1,391.7 | $73.4 | 5.3% |
| Knees | $828.6 | $792.9 | $35.6 | 4.5% |
| Hips | $524.0 | $495.7 | $28.3 | 5.7% |
| Extremities | $112.5 | $103.1 | $9.5 | 9.2% |
| Trauma | $229.1 | $188.7 | $40.4 | 21.4% |
| Sports Medicine | $63.3 | $56.5 | $6.8 | 12% |
| Orthobiologics | $25.3 | $23.5 | $1.8 | 7.6% |
| Enabling Technology | $29.2 | $22.5 | $6.7 | 29.9% |
| Other | $274.7 | $226.3 | $48.5 | 21.4% |
| Total | $2,086.7 | $1,909.1 | $177.5 | 9.3% |
Orthopedic Sales by Geography
| Region | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,209.4 | $1,113.6 | $95.8 | 8.6% |
| OUS | $877.3 | $795.5 | $81.8 | 10.3% |
| EMEA | $516.5 | $458.2 | $58.3 | 12.7% |
| APAC | $266.1 | $253.0 | $13.1 | 5.2% |
| ROW | $94.8 | $84.4 | $10.4 | 12.3% |
| Total | $2,086.7 | $1,909.1 | $177.5 | 9.3% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $2,086.7 | |
| Cost of Sales | $576.2 | 27.6% |
| Selling and Admin | $849.9 | 40.7% |
| R & D | $103.4 | 5% |
| Other | $319.1 | 15.3% |
| Net Earnings | $238.1 | 11.4% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
